Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q2 VYJUVEK revenue rises 24% to $119.2 million; net income $54.8 million

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported second quarter 2026 results on August 3, 2026. VYJUVEK net product revenue rose 24% from the prior year quarter to $119.2 million, and net income was $54.8 million, or $1.79 per diluted share, versus $38.3 million a year earlier. The company also gave full-year 2026 non-GAAP R&D and SG&A expense guidance of $175.0 million to $195.0 million.

Key points

  • Q2 2026 product revenue, net was $119.2 million, up from $96.0 million in Q2 2025
  • Q2 2026 net income was $54.8 million, or $1.79 per diluted share, versus $1.29 a year earlier
  • First-half 2026 product revenue was $235.6 million, up from $184.2 million; cash and investments totaled $1.1 billion at June 30, 2026
  • FY 2026 non-GAAP R&D and SG&A expense guidance is $175.0 million to $195.0 million, excluding stock-based compensation

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECAug 3, 2026, 7:04 AM ET
Accession number0001711279-26-000058

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.